Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 456.40K | 431.50K | -135.00K | -135.00K | 621.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.43M | 1.32M | 391.00K | 391.00K | 1.15M |
| Operating Income | -1.43M | -1.32M | -391.00K | -391.00K | -1.15M |
| Income Before Tax | 559.10K | -3.25M | -112.70K | -112.70K | -1.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 559.10K | -3.25M | -112.70K | -112.70K | -1.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 559.10K | -3.25M | -112.70K | -112.70K | -1.81M |
| EBIT | -1.43M | -1.32M | -391.00K | -391.00K | -1.15M |
| EBITDA | -1.43M | -1.32M | -387.30K | -387.30K | -1.14M |
| EPS Basic | 0.02 | -0.12 | -0.01 | -0.01 | -12.96 |
| Normalized Basic EPS | 0.01 | -0.07 | -0.01 | -0.01 | -6.48 |
| EPS Diluted | 0.02 | -0.12 | -0.01 | -0.01 | -12.96 |
| Normalized Diluted EPS | 0.01 | -0.07 | -0.01 | -0.01 | -6.48 |
| Average Basic Shares Outstanding | 29.67M | 28.22M | 17.86M | 17.86M | 139.30K |
| Average Diluted Shares Outstanding | 29.67M | 28.22M | 17.86M | 17.86M | 139.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |